| scholarly article | Q13442814 |
| P2093 | author name string | He Zhu | |
| Song Wang | |||
| Haiyang Zhang | |||
| Gottfried Konecny | |||
| Mitchell Kamrava | |||
| Nicholas Cacalano | |||
| Qiuju Liu | |||
| Michael Xie | |||
| Shunzi Jin | |||
| P2860 | cites work | Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach | Q79329241 |
| Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study | Q81780938 | ||
| The xCELLigence system for real-time and label-free monitoring of cell viability | Q83790178 | ||
| (S034) Pilot Phase II Trial of "Sandwich" Radiation and Combination Carboplatin and Paclitaxel Chemotherapy in Patients With High-Risk Endometrial Cancer | Q95368961 | ||
| PTEN regulatory functions in tumor suppression and cell biology | Q28284719 | ||
| Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| The functions and regulation of the PTEN tumour suppressor | Q29615536 | ||
| PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model | Q32069431 | ||
| Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma | Q33180279 | ||
| Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). | Q33377350 | ||
| Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity | Q33774967 | ||
| Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes | Q33855646 | ||
| Signalling pathways in endometrial cancer | Q34721660 | ||
| The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis | Q34786625 | ||
| High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability | Q35275603 | ||
| Sequential chemotherapy and radiotherapy in the sandwich method for advanced endometrial cancer: a meta-analysis | Q35612775 | ||
| G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy | Q36176979 | ||
| Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells | Q36510153 | ||
| Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies | Q36554430 | ||
| Dynamic and label-free cell-based assays using the real-time cell electronic sensing system | Q36658140 | ||
| Drug-sensitive FGFR2 mutations in endometrial carcinoma | Q36735178 | ||
| PI3K pathway dependencies in endometrioid endometrial cancer cell lines | Q36980561 | ||
| The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies | Q37349623 | ||
| Emerging therapeutic targets in endometrial cancer | Q37827340 | ||
| Contemporary management of endometrial cancer | Q37996608 | ||
| Markers for individualised therapy in endometrial carcinoma | Q38030768 | ||
| The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer | Q38053414 | ||
| Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer | Q38242086 | ||
| PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer. | Q38882236 | ||
| Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells | Q39188104 | ||
| Cell cycle-dependent antagonistic interactions between paclitaxel and gamma-radiation in combination therapy | Q40532790 | ||
| Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study | Q40533016 | ||
| Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients | Q40535566 | ||
| A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma | Q43104465 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | docetaxel | Q420436 |
| endometrial cancer | Q944777 | ||
| P304 | page(s) | 2111 | |
| P577 | publication date | 2019-02-14 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines | |
| P478 | volume | 9 |
| Q90179383 | Cyclooxygenase-2 and β-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer | cites work | P2860 |
Search more.